<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cholesteryl <z:chebi fb="21" ids="35701">ester</z:chebi> transfer protein (CETP) transfers cholesteryl <z:chebi fb="21" ids="35701">esters</z:chebi> from <z:chebi fb="17" ids="39025">HDL</z:chebi> to <z:chebi fb="1" ids="39027">VLDL</z:chebi> and <z:chebi fb="15" ids="39026">LDL</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="16247">Phospholipid</z:chebi> transfer protein (PLTP) transfers <z:chebi fb="1" ids="16247">phospholipids</z:chebi> between <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>, converts HDL3 into larger and smaller particles, and is involved in pre-beta-<z:chebi fb="17" ids="39025">HDL</z:chebi> generation </plain></SENT>
<SENT sid="2" pm="."><plain>We examined the effects of 24-h <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> (30 mU x kg(-1) x h(-1)) and 24-h Acipimox (250 mg/4 h) on plasma <z:chebi fb="23" ids="18059">lipids</z:chebi> as well as CETP and PLTP activities (measured with exogenous substrate assays) in eight healthy and eight type 2 diabetic subjects </plain></SENT>
<SENT sid="3" pm="."><plain>After 24 h of insulin, plasma free fatty acids (FFAs), <z:chebi fb="4" ids="47775">HDL cholesterol</z:chebi>, and plasma <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> AI decreased in healthy subjects and type 2 diabetic patients (P &lt; 0.05) </plain></SENT>
<SENT sid="4" pm="."><plain>Plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi> did not significantly change in either group </plain></SENT>
<SENT sid="5" pm="."><plain>After 24 h of Acipimox, <z:hpo ids='HP_0000001'>all</z:hpo> parameters, including plasma <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, decreased in both groups (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>Insulin decreased plasma PLTP activity by 17.6% after 24 h in healthy subjects (P &lt; 0.05) and 10.2% in diabetic patients (P &lt; 0.05 vs. baseline; P &lt; 0.05 vs. healthy subjects) </plain></SENT>
<SENT sid="7" pm="."><plain>Acipimox lowered PLTP activity by 10.3% in healthy subjects (P &lt; 0.05) and 11.3% in diabetic patients (P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>When insulin was infused for 3 h after Acipimox, a further decrease was found only in healthy subjects </plain></SENT>
<SENT sid="9" pm="."><plain>Plasma CETP activity decreased by 9.5% after 24 h of insulin in healthy subjects (P &lt; 0.05), but not in diabetic patients </plain></SENT>
<SENT sid="10" pm="."><plain>Acipimox did not decrease plasma CETP activity in either group </plain></SENT>
<SENT sid="11" pm="."><plain>In healthy subjects, the PLTP responses with insulin and Acipimox were larger than the changes in CETP activity (P &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>These findings suggest that there is a metabolic link between the regulation of plasma FFA and PLTP, but not CETP </plain></SENT>
<SENT sid="13" pm="."><plain>The PLTP response to insulin is blunted in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>